SUMMARY OF PRODUCT CHARACTERISTICS

1.

NAME OF THE VETERINARY MEDICINAL PRODUCT

Oxycare Tablets 100mg

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance(s) :

Oxytetracyline dihydrate

Excipient(s) :

Titanium dioxide (E171)

Tartrazine Lake 15002 (E102)

For a full list of excipients, see section 6.1

100mg

1.4mg

0.8mg

3.

PHARMACEUTICAL FORM

Tablet

A yellow, sugar-coated, biconvex tablet.

4.

CLINICAL PARTICULARS

4.1

Target species

Dogs

4.2

Indications for use, specifying the target species

For the treatment of dogs with bacterial infections sensitive to tetracycline

therapy only. Soft tissue infections caused by Staphylococcus aureus or

Streptococcus spp. have been shown to be highly sensitive. Respiratory

infections caused by Bordetella bronchiseptica are also commonly sensitive.

4.3

Contraindications

Contraindicated for use in animals with hypersensitivity to any tetracycline.

4.4

Special warnings for each target species

Not applicable.

4.5

Special precautions for use

i.

Special precautions for use in animals

Oxytetracycline is deposited in growing teeth and bones and may cause yellow discolouration. It also crosses the placenta. For this reason it is not recommended in late pregnancy or in young animals. Caution must be taken in treating animals with renal or hepatic dysfunction; in such cases it may be necessary to reduce dosage levels.

ii.

Special precautions for the person administering the veterinary medicinal product to animals

If you know you are hypersensitive (allergic) to oxytetracycline, do not handle the product.

In the event of accidental ingestion, flush mouth with plenty of water and seek medical advice.

In the event of eye contact, flush thoroughly with clean, running water. If irritation persists seek medical attention.

Wash hands after use.

iii.

Other precautions

None

4.6

Adverse reactions (frequency and seriousness)

Prolonged use of antibiotics of all types may promote the overgrowth of

non-susceptible organisms to that antibiotic. Where it occurs therapy should be discontinued and appropriate control of the organisms substituted.

4.7

Use during pregnancy, lactation or lay

Oxytetracycline crosses the placenta. The product should not be used in late pregnancy.

4.8

Interaction with other medicinal products and other forms of interaction

The product must not be given concurrently with milk or antacids.

4.9

Amount(s) to be administered and administration route

For oral administration

An initial dose of 50mg/kg bodyweight should be given, followed by subsequent doses of 25mg/kg every 12 hours for 5 days. To be taken by mouth at least one hour before or two hours after feeding.

4.10

Overdose (symptoms, emergency procedures, antidotes), if necessary

Gastric lavage may be beneficial in the first hours after ingestion and milk will reduce absorption. Thereafter conservative treatment.

4.11

Withdrawal period(s)

Not applicable.

5.

PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Oxytetracycline

ATC Vet Code: QJ01AA06

5.1

Pharmacodynamic properties

Antibiotic of the tetracycline group, with a broad spectrum of activity against Mycoplasma, Chlamydia and Rickettsia and a range of Gram-positive and Gram-negative bacteria. (Little activity against E. coli, Salmonella, Proteus and Pseudomonads.) Tetracyclines are bacteriostatic; bacterial sensitivity testing is advisable to preclude resistance in the target infecting bacteria.

6.

PHARMACEUTICAL PARTICULARS

6.1

List of excipients

Coating

Tartrazine Lake 15002 (E102)

Titanium Dioxide (E171)

Sucrose

Talc

White Beeswax

Carnauba Wax

Glucose Monohydrate

Povidone

Liquid Paraffin

Sodium Starch Glycollate Type A

Maize Starch

Stearic Acid

Magnesium Stearate

IMS 74 OP